A team of Skadden, Arps, Slate, Meagher & Flom litigators last week beat back a putative federal securities class action in North Carolina against biopharmaceutical company Cempra, Inc.

The company and its top executives were sued for making allegedly false and misleading statements about the safety of the company’s lead product, solithromycin. The drug is being developed for the treatment of community-acquired bacterial pneumonia (the leading cause of death due to infection in the United States).